| First Author | Kyrmizi I | Year | 2013 |
| Journal | J Leukoc Biol | Volume | 94 |
| Issue | 4 | Pages | 751-7 |
| PubMed ID | 23898046 | Mgi Jnum | J:205306 |
| Mgi Id | MGI:5544543 | Doi | 10.1189/jlb.0113039 |
| Citation | Kyrmizi I, et al. (2013) Tpl2 kinase regulates FcgammaR signaling and immune thrombocytopenia in mice. J Leukoc Biol 94(4):751-7 |
| abstractText | The MAPK3 Tpl2 controls innate and adaptive immunity by regulating TLR, TNF-alpha, and GPCR signaling in a variety of cell types. Its ablation gives rise to an anti-inflammatory phenotype characterized by resistance to LPS-induced endotoxin shock, DSS-induced colitis, and TNF-alpha-induced IBD. Here, we address the role of Tpl2 in autoimmunity. Our data show that the ablation and the pharmacological inhibition of Tpl2 protect mice from antiplatelet antibody-induced thrombocytopenia, a model of ITP. Thrombocytopenia in this model and in ITP is caused by phagocytosis of platelets opsonized with antiplatelet antibodies and depends on FcgammaR activation in splenic and hepatic myeloid cells. Further studies explained how Tpl2 inhibition protects from antibody-induced thrombocytopenia, by showing that Tpl2 is activated by FcgammaR signals in macrophages and that its activation by these signals is required for ERK activation, cytoplasmic Ca(2+) influx, the induction of cytokine and coreceptor gene expression, and phagocytosis. |
